You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Drug to target hardest-to-kill cancer cells

Chemotherapy and other traditional cancer therapies do a great job of shrinking most tumors. But some cancer cells manage to escape and seed new tumor growth — a problem that has vexed scientists for years.

Now a Cambridge start-up is going to test a drug it hopes will target those cancer cells that survive the first salvo. The firm, Verastem Inc., has just begun recruiting patients with ovarian cancer for a clinical trial in which it will test its drug, along with chemotherapy, to see if the combination produces a more complete and effective treatment.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week